RUNX2 transcription factor inhibitors and uses thereof
US11634381B2 · kind B2 · utility
0Cited by
1References
5Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | May 3, 2019 |
| Grant date | Apr 25, 2023 |
| Priority date | — |
| Expiry date | May 3, 2039 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07C2603/94
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Provide herein are compounds with a general chemical structure of: Substituents R1 and R2 independently are H, Cl, F, Br, CH3, CF3, SH, —N(C1-3alkyl)2, —NHC(O)C1-3alkyl, or —NHC(O)C5-7cycloalkyl, substituent R3 is H or C1-3 alkyl and R4 is a bridged cycloalkene such as a bridged cyclohexene or a bridge-substituted cyclohexene. The compounds are therapeutics to treat a cancer, such as breast cancer, or metastatic cancers, to inhibit RUNX2 activity, such as protein expression, in a cancer cell and to increase survival of a subject with breast cancer.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.